MiMedx Group Inc - Product Pipeline Analysis, 2018 Uate

Summary

MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary purion process that separates placental tissues, cleans and reassembles layers, and dehydrates the tissue to preserve the key elements associated with healing. MiMedx’s product delivers human extracellular matrix components for regeneration of damaged or diseased tissues. Its products modulate inflammation, reduce scar tissue formation, and enhance healing. The company offers services in the areas of wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. MiMedx is headquartered in Marietta, Georgia, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company MiMedx Group Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


  • MiMedx Group Inc Company Overview
    • MiMedx Group Inc Company Snapshot
    • MiMedx Group Inc Pipeline Products and Ongoing Clinical Trials Overview
      • Table MiMedx Group Inc Pipeline Products and Ongoing Clinical Trials Overview
      • Table MiMedx Group Inc Pipeline Products by Equipment Type
      • Table Figure 1: MiMedx Group Inc Pipeline Products by Equipment Type
      • Table MiMedx Group Inc Pipeline Products by Indication
  • MiMedx Group Inc – Pipeline Analysis Overview
    • MiMedx Group Inc - Key Facts
      • Table MiMedx Group Inc, Key Facts
    • MiMedx Group Inc - Major Products and Services
      • Table MiMedx Group Inc, Major Products and Services
    • MiMedx Group Inc Pipeline Products by Development Stage
      • Table Figure 2: MiMedx Group Inc Pipeline Products by Development Stage
      • Table MiMedx Group Inc Number of Pipeline Products by Development Stage
      • Table MiMedx Group Inc Pipeline Products Summary by Development Stage
    • MiMedx Group Inc Ongoing Clinical Trials by Trial Status
      • Table Figure 3: MiMedx Group Inc Ongoing Clinical Trials by Trial Status
      • Table MiMedx Group Inc Ongoing Clinical Trials by Trial Status
      • Table MiMedx Group Inc Ongoing Clinical Trials Summary
  • MiMedx Group Inc Pipeline Products Overview
    • AmnioFix Injectable - Achilles Tendonitis
      • AmnioFix Injectable - Achilles Tendonitis Product Overview
        • Table AmnioFix Injectable - Achilles Tendonitis - Product Status
        • Table AmnioFix Injectable - Achilles Tendonitis - Product Description
      • AmnioFix Injectable - Achilles Tendonitis Clinical Trial
        • Table AmnioFix Injectable - Achilles Tendonitis - A Phase III Achilles Tendonitis Clinical Study of Investigational New Drug (IND)
    • AmnioFix Injectable - Knee OA Pain
      • AmnioFix Injectable - Knee OA Pain Product Overview
        • Table AmnioFix Injectable - Knee OA Pain - Product Status
        • Table AmnioFix Injectable - Knee OA Pain - Product Description
      • AmnioFix Injectable - Knee OA Pain Clinical Trial
        • Table AmnioFix Injectable - Knee OA Pain - A Phase IIb, Prospective, Double-blinded, Randomized Controlled Study of Regenerative Medicine Advanced Therapy (RMAT) Designated AmnioFix Injectable in the Treatment of Knee Osteoarthritis
    • AmnioFix Injectable - Plantar Fasciitis
      • AmnioFix Injectable - Plantar Fasciitis Product Overview
        • Table AmnioFix Injectable - Plantar Fasciitis - Product Status
        • Table AmnioFix Injectable - Plantar Fasciitis - Product Description
      • AmnioFix Injectable - Plantar Fasciitis Clinical Trial
        • Table AmnioFix Injectable - Plantar Fasciitis - A Prospective, Single-blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to the Saline Placebo Injection in the Treatment of Plantar Fasciitis
        • Table AmnioFix Injectable - Plantar Fasciitis - Prospective, Double-blinded, Randomized Controlled Trial of AmnioFix Injectable as Compared to a Saline Placebo Injection in the Treatment of Plantar Fasciitis
    • AmnioFix Injectable - Pressure Ulcer
      • AmnioFix Injectable - Pressure Ulcer Product Overview
        • Table AmnioFix Injectable - Pressure Ulcer - Product Status
        • Table AmnioFix Injectable - Pressure Ulcer - Product Description
    • CollaFix - Foot & Ankle
      • CollaFix - Foot & Ankle Product Overview
        • Table CollaFix - Foot & Ankle - Product Status
        • Table CollaFix - Foot & Ankle - Product Description
    • CollaFix - Rotator Cuff Repair
      • CollaFix - Rotator Cuff Repair Product Overview
        • Table CollaFix - Rotator Cuff Repair - Product Status
        • Table CollaFix - Rotator Cuff Repair - Product Description
    • CollaFix BioBraid
      • CollaFix BioBraid Product Overview
        • Table CollaFix BioBraid - Product Status
        • Table CollaFix BioBraid - Product Description
    • CollaFix Collagen Fiber Suture
      • CollaFix Collagen Fiber Suture Product Overview
        • Table CollaFix Collagen Fiber Suture - Product Status
        • Table CollaFix Collagen Fiber Suture - Product Description
    • CollaFix Tendon Protector
      • CollaFix Tendon Protector Product Overview
        • Table CollaFix Tendon Protector - Product Status
        • Table CollaFix Tendon Protector - Product Description
    • EpiFix Amniotic Membrane Allograft
      • EpiFix Amniotic Membrane Allograft Product Overview
        • Table EpiFix Amniotic Membrane Allograft - Product Status
        • Table EpiFix Amniotic Membrane Allograft - Product Description
      • EpiFix Amniotic Membrane Allograft Clinical Trial
        • Table EpiFix Amniotic Membrane Allograft - Clinical Evaluation of EpiFix in venous leg ulcers ("VLUs")
        • Table EpiFix Amniotic Membrane Allograft - Dehydrated Human Amnion Chorion Membrane (dHACM) Versus Control in the Treatment of Partial Thickness Burns
        • Table EpiFix Amniotic Membrane Allograft - Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane
        • Table EpiFix Amniotic Membrane Allograft - The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers
    • SaluDisc
      • SaluDisc Product Overview
        • Table SaluDisc - Product Status
        • Table SaluDisc - Product Description
  • MiMedx Group Inc - Key Competitors
  • MiMedx Group Inc - Key Employees
    • Table MiMedx Group Inc, Key Employees
  • MiMedx Group Inc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
      • Table MiMedx Group Inc, Subsidiaries
  • Recent Developments
    • MiMedx Group Inc, Recent Developments
      • Jul 02, 2018: MiMedx Announces Leadership Changes And Corporate Actions
      • Jun 07, 2018: MiMedx Announces Executive to Lead its International Operations and Provides Update on Company's International Progress
      • Jun 07, 2018: MiMedx to restate certain historical financial statements
      • Apr 26, 2018: MiMedx Reports Unreviewed First Quarter Revenue Exceeded Upper End Of Its Guidance
      • Mar 28, 2018: MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix Injectable For The Treatment Of Osteoarthritis Of The Knee
      • Mar 15, 2018: MiMedx Announces Expectation to Exceed the $92 Million Top End of First Quarter Revenue Guidance
      • Mar 09, 2018: AmnioFix Injectable Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for the Treatment of Osteoarthritis of the Knee
      • Mar 02, 2018: MiMedx Receives Notice of Filing Delinquency from NASDAQ
      • Jan 17, 2018: MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix Injectable for Achilles Tendonitis
      • Jan 16, 2018: MiMedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of AmnioFix Injectable In Patients With Recalcitrant Plantar Fasciitis Pain
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook